期刊文献+

外周血干细胞样记忆性T细胞在肾癌患者中的表达水平及临床意义 被引量:2

Expression and Clinical Significance of Peripheral Blood Stem-like Memory T Cells in Patients with Renal Cell Carcinoma
下载PDF
导出
摘要 目的研究肾癌患者外周血干细胞样记忆性T细胞(stem-like memory T cells,TSCM)的分布特征,探讨TSCM与临床病理特征的关系。方法选取2019年1月~2020年3月连云港第一人民医院收治的65例肾癌患者为肾癌组,同期30例健康志愿者为健康组。运用流式细胞术检测两组患者外周血中初始T细胞(naive T cells,TN)和TSCM比例,比较肾癌组与健康组的差异,分析TSCM、TN和TSCM/TN值与临床病理特征的关系。结果与健康组比较,肾癌组患者外周血TSCM比例(0.15%±0.06%vs 0.20%±0.11%,t=2.524,P<0.05)和TN比例(2.66%±1.18%vs 6.29%±1.58%,t=12.499,P<0.01)均明显降低,TSCM/TN值(6.48%±3.70%vs 3.31%±1.82%,t=5.600,P<0.01)明显升高。肾癌患者中,TSCM比例与肿瘤TNM分期(r=-0.258,P<0.05)和Fuhrman核分级(r=-0.271,P<0.05)呈负相关;TN比例与肿瘤TNM分期(r=-0.447,P<0.01)和Fuhrman核分级(r=-0.263,P<0.05)呈负相关;TSCM/TN值与肿瘤TNM分期(r=0.433,P<0.01)呈正相关。结论肾癌患者外周血TSCM、TN及TSCM/TN值与肿瘤TNM分期和Fuhrman核分级密切相关,可用于评估肿瘤发生、发展情况,TSCM在肾癌的过继性免疫治疗中具有广阔的应用前景。 Objective To study the expression of peripheral blood stem-like memory T cells(TSCM)in patients with renal cell carcinoma and to analyze their relationship to clinicopathological characteristics.Methods From January 2019 to March 2020,there were 65 patients with renal cell carcinoma in the First People′s Hospital of Lianyungang served as renal cell carcinoma group and 30 healthy volunteers as healthy group.The percentages of naive T cells(TN)and TSCM in the peripheral blood were detected by flow cytometry and the differences between the two groups were compared.The relationship of clinicopathological features to TSCM,TN and TSCM/TN ratio was analyzed.Results Compared with healthy group,the percentages of TSCM(0.15%±0.06%vs 0.20%±0.11%,t=2.524,P<0.05)and TN(2.66%±1.18%vs 6.29%±1.58%,t=12.499,P<0.01)in peripheral blood of the renal cell carcinoma patients decreased significantly,while the ratio of TSCM to TN(6.48%±3.70%vs 3.31%±1.82%,t=5.600,P<0.01)increased significantly.The proportion of TSCM was negatively correlated with tumor TNM stage(r=-0.258,P<0.05)and Fuhrman grade(r=-0.271,P<0.05).The proportion of TN was negatively correlated with tumor TNM stage(r=-0.447,P<0.01)and Fuhrman grade(r=-0.263,P<0.05).The ratio of TSCM to TN was positively correlated with tumor TNM stage(r=0.433,P<0.01).Conclusion TSCM,TN and the ratio of TSCM to TN in peripheral blood of patients with renal cell carcinoma are closely related to tumor TNM stage and Fuhrman grade,which could be used to evaluate the occurrence and development of tumor.TSCM might have important clinical application value in adaptive or engineered cell immunotherapy of renal cell carcinoma.
作者 陈婷 黄小雨 杨栋梁 孙方浒 蒋晓东 Chen Ting;Huan Xiaoyu;Yang Dongliang(Graduate School of Xuzhou Medical University,Jiangsu 221004,China)
出处 《医学研究杂志》 2021年第5期76-79,137,共5页 Journal of Medical Research
基金 江苏省研究生实践创新计划项目(SJCX190943)。
关键词 肾癌 干细胞样T细胞 初始T细胞 T淋巴细胞亚群 细胞免疫 Renal cell carcinoma Stem-like memory T cells Naive T cells T-lymphocyte subset Cellular immunity
  • 相关文献

参考文献8

二级参考文献30

  • 1王欢,周芳坚,王其京,秦自科,黄丽惜,刘卓炜,韩辉,李永强,陈诗萍,夏建川.负载自体肿瘤细胞裂解物的DC疫苗联合CIK治疗晚期肾癌的临床观察——附10例报告[J].癌症,2006,25(5):625-630. 被引量:51
  • 2郭三维,董柏君,黄翼然.肾癌预后分析的研究进展[J].国际泌尿系统杂志,2006,26(3):309-315. 被引量:12
  • 3Jemal A, Bray F, Center M M, et al. Global cancer statistics[J]. CA CancerJ Clin, 2011, 61(2): 69-90.
  • 4Uchida K, Miyao N, Masumori N, et al. Recurrence of renal cell carcinoma more than 5 years after nephrectomy[J]. Int J Urol, 2002, 9(1): 19-23.
  • 5GarciaJ A, Rini B I. Recent progress in the management of advanced renal cell carcinoma[J].CA CancerJ Clin, 2007, 57(2): 112-125.
  • 6Hontscha C, Borck Y, Zhou H, et al. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC)[J].J Cancer Res Clin Oncol,2011,137(2):305-310.
  • 7Li H, Wang C, Yu j, et al. Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery[J]. Cytotherapy, 2009, 11(8): 1076-1083.
  • 8Ren X, YuJ, Liu H, et al. Thl bias in PBMC induced by multicy- cles of auto-CIKs infusion in malignant solid tumor patients[J]. Cancer Biother Radiopharm, 2006, 21(1):22-33.
  • 9Motzer R J, Bacik J, Murphy B A, et al. Interferon-alfa as a com- parative treatment for chnical trials of new therapies against ad- vanced renal cell carcinoma[J].J Clin Oncol, 2002, 20(1): 289-296.
  • 10Sabatino M, Kim-Schulze S, Panelli M C, et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to I high-dose interleukin-2 therapy[J]. J Clin Oncol, 2009, 27(16): 2645-2652.

共引文献51

同被引文献16

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部